Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jan:133:99-111.
doi: 10.1016/j.critrevonc.2018.11.002. Epub 2018 Nov 15.

Advanced stage melanoma therapies: Detailing the present and exploring the future

Chelsea Luther  1 , Umang Swami  2 , Jun Zhang  2 , Mohammed Milhem  2 , Yousef Zakharia  3
Affiliations
Review

Advanced stage melanoma therapies: Detailing the present and exploring the future

Chelsea Luther et al. Crit Rev Oncol Hematol. 2019 Jan.

Abstract

Metastatic melanoma therapies have proliferated over the last ten years. Prior to this, decades passed with only very few drugs available to offer our patients, and even then, those few drugs had minimal survival benefits. Many treatment options emerged over the last ten years with diverse mechanisms of action. Further, combination regimens have demonstrated superiority over monotherapy, especially for targeted agents. Each therapeutic combination possesses different advantages and side effect profiles. In this review, we outline the United States Food and Drug Administration-approved melanoma treatment agents and therapies currently in clinical development, focusing on combination approaches.

Keywords: BRAF; CTLA-4; Combination therapy; Dabrafenib; Epacadostat; Immunotherapy; Indoleamine 2,3-dioxygenase; Indoximod (D-1MT); Ipilimumab; MEDI4736; Metastatic melanoma; Nivolumab; PD1; Pembrolizumab; TVEC; Talimogene; Targeted therapy; Vemurafenib.

PubMed Disclaimer

MeSH terms

Substances